Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Burt Nabors

Showing results (51-60 of 152) with videos related to

Pageof 16
Sort By:
Journal of Neuro-Oncology|February 10, 2018
Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?Caroline Happold, Thierry Gorlia, L Burt Nabors, et al.
Research Square|February 23, 2026
Postoperative Seizure in Patients with Malignant Glioma Undergoing Tumor Resection with Intraoperative Mapping: Risk Factors, Management Strategies, and the Utility of Bayesian Analysis in a Case-Control CohortYifei Sun, Mina Lobbous, Kristen Riley, et al.
Neuro-Oncology Practice|March 20, 2025
Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?Marjolein Geurts, Luzia Berchtold, Franz Koenig, et al.
Molecular Cancer Therapeutics|December 17, 2002
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiationCarmelo Blanquicett, G Yancey Gillespie, L Burt Nabors, et al.
Neuro-Oncology Advances|August 11, 2022
Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastomaKatharina Seystahl, Felix Boakye Oppong, Emilie Le Rhun, et al.
Neuro-Oncology|March 21, 2022
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastomaEmilie Le Rhun, Felix Boakye Oppong, Maureen Vanlancker, et al.
Neuro-Oncology|June 26, 2008
Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomasStuart A Grossman, Kathryn A Carson, Surasak Phuphanich, et al.
Neuro-Oncology Practice|August 9, 2020
Capacity to consent to research participation in adults with metastatic cancer: comparisons of brain metastasis, non-CNS metastasis, and healthy controlsKyler Mulhauser, Dario A Marotta, Adam Gerstenecker, et al.
Journal of Neuroimmunology|March 27, 2012
Sex hormone-dependent attenuation of EAE in a transgenic mouse with astrocytic expression of the RNA regulator HuRCrystal Wheeler, L Burt Nabors, Scott Barnum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Treatment of relapsed central nervous system lymphoma with high-dose methotrexateScott R Plotkin, Rebecca A Betensky, Fred H Hochberg, et al.
Pageof 16

Showing results (51-60 of 152) with videos related to

Sort By:
Pageof 16
Journal of Neuro-Oncology|February 10, 2018
Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?Caroline Happold, Thierry Gorlia, L Burt Nabors, et al.
Research Square|February 23, 2026
Postoperative Seizure in Patients with Malignant Glioma Undergoing Tumor Resection with Intraoperative Mapping: Risk Factors, Management Strategies, and the Utility of Bayesian Analysis in a Case-Control CohortYifei Sun, Mina Lobbous, Kristen Riley, et al.
Neuro-Oncology Practice|March 20, 2025
Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?Marjolein Geurts, Luzia Berchtold, Franz Koenig, et al.
Molecular Cancer Therapeutics|December 17, 2002
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiationCarmelo Blanquicett, G Yancey Gillespie, L Burt Nabors, et al.
Neuro-Oncology Advances|August 11, 2022
Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastomaKatharina Seystahl, Felix Boakye Oppong, Emilie Le Rhun, et al.
Neuro-Oncology|March 21, 2022
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastomaEmilie Le Rhun, Felix Boakye Oppong, Maureen Vanlancker, et al.
Neuro-Oncology|June 26, 2008
Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomasStuart A Grossman, Kathryn A Carson, Surasak Phuphanich, et al.
Neuro-Oncology Practice|August 9, 2020
Capacity to consent to research participation in adults with metastatic cancer: comparisons of brain metastasis, non-CNS metastasis, and healthy controlsKyler Mulhauser, Dario A Marotta, Adam Gerstenecker, et al.
Journal of Neuroimmunology|March 27, 2012
Sex hormone-dependent attenuation of EAE in a transgenic mouse with astrocytic expression of the RNA regulator HuRCrystal Wheeler, L Burt Nabors, Scott Barnum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Treatment of relapsed central nervous system lymphoma with high-dose methotrexateScott R Plotkin, Rebecca A Betensky, Fred H Hochberg, et al.
Pageof 16